Innoforce is a biopharmaceutical CDMO specializing in RNA, plasmid DNA, and cell and gene therapies, with facilities in Hangzhou, China, and Maryland, U.S. Founded in 2018, the company provides end-to-end services including process development, GMP manufacturing of RNA, plasmid DNA, viral vectors, and cell products, as well as LNP formulation using proprietary technologies. Innoforce partners with clients globally to deliver tailored solutions for advanced therapy development and commercialization. Out of business as of October, 2025